BioStock: Cereno Scientific – a rare opportunity in cardiovascular diseases
Cardiovascular diseases (CVD) are the most common cause of death in the world. An estimated 17,9 million people are expected to die every year, a figure that is forecasted to rise to 22,2 million by 2030. Gothenburg-based biotech company Cereno Scientific is developing new a new class of therapies in CVD, using an epigenetic modulation platform. Earlier this year, the FDA granted Cereno Scientific orphan drug designation-status (ODD) for its leading clinical phase II candidate CS1 in pulmonary arterial hypertension (PAH). BioStock has now published a company update on Cereno Scientific.Read
Kaarea and Oral Hammaslääkärit have joined Kiilto’s development project and started recycling plastic materials they use. A follow-up to the successful pilot project is already in the works.Spaghetti bolognaise is being prepared today at the Turku University Hospital nutrition centre. Special diets are catered for with separate foods, such as pureed soups that are easier to swallow. Kaarea employees, who are responsible for the hospital’s food service, also prepare the meals for the staff canteen.
According to Kaarea service manager Sanna Lainela, special attention is naturally paid to
